April 28, 2015—The Health Resources and Services Administration has asked drugmakers to verify by May 15 that their information in the 340B program database is complete and up to date. … [Read more...]
HRSA Submits 340B Information Collection Request to White House
Next step in road to creating ceiling price websiteApril 22, 2015 --The Health Resources and Services Administration has submitted an information collection request to the Office of Management and Budget for its review and approval. … [Read more...]
PhRMA Calls Again for Vacating 340B Orphan Drug Rule
Drugmakers request a hearing before judgeApril 16, 2015—The Department of Health and Human Services' 340B orphan drug exclusion interpretive rule violates the 340B statute's plain language and forces drugmakers either to obey "or face an enforcement action where HHS will be the government lawyer, the judge, and the jury," drugmakers say in a new court filing. … [Read more...]
OIG to Investigate Rising Generic Drug Prices
Will determine effect of extending Medicaid rebate inflation penalty to genericsApril 15, 2015—The Department of Health and Human Services Office of Inspector General has told two members of Congress that it plans to determine the amount of additional rebates Medicaid would have received if generic drugs were subject to the same penalty as brand-name drugs when their prices rise faster than the rate of inflation. … [Read more...]
U.S. Drug Spending Soared 13% Last Year to $374 Billion
Study cites expensive new specialty meds as a primary driverApril 14, 2015—U.S. drug spending increased by 13 percent in 2014 to just under $374 billion – the biggest year-to-year spike since 2001, according to a new report. … [Read more...]
Experts Decry “Unsustainable” Drug Prices
Consensus emerges on need for drug payments to reflect valueApril 9, 2015—The coming "tsunami" of high-priced specialty drugs for cancer and other chronic conditions threatens to undermine the U.S. healthcare system's financial integrity, a panel representing physicians, patients, and payers warned at a Capitol Hill briefing today organized by the Campaign for Sustainable Rx Pricing. … [Read more...]
340B Rule on Civil Fines for Drugmakers Moves Closer to Release
HRSA sends proposed regulation to White House for reviewApril 8, 2015—The Health Resources and Services Administration took a step this morning toward launching a long-delayed system of civil fines for drugmakers that deliberately overcharge for 340B drugs, plus guidance on the calculation of 340B ceiling prices. … [Read more...]